83 results
8-K
EX-99.1
COGT
Cogent Biosciences Inc
26 Feb 24
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
8:30am
requirements into 2027, including through clinical readouts from the ongoing SUMMIT, PEAK and APEX registration-directed trials.
R&D Expenses: Research … and development expenses were $48.7 million for the fourth quarter of 2023 and $173.8 million for the year ended December 31, 2023, as compared
8-K
EX-99.1
COGT
Cogent Biosciences Inc
14 Feb 24
Cogent Biosciences Announces Oversubscribed $225 Million Private Placement
8:35am
.
Cogent intends to use the net proceeds from the proposed financing to fund research and development, activities relating to bezuclastinib and other
8-K
EX-99.1
1k8p cvze
2 Nov 23
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2023 Financial Results
9:18am
8-K
EX-99.1
dam13ns5l
8 Aug 23
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2023 Financial Results
8:14am
424B5
s0ikpf31cav ei2uv7p
8 Jun 23
Prospectus supplement for primary offering
4:01pm
424B5
r39cnuv
6 Jun 23
Prospectus supplement for primary offering
5:22pm
8-K
EX-99.1
rcfa2t08sy2w6udno4w3
9 May 23
Cogent Biosciences Reports Recent Business Highlights and First Quarter
8:13am
8-K
EX-99.2
rzck7q 2kt12p0o0
12 Dec 22
Cogent Biosciences Announces Positive Updated Clinical Data from Ongoing Phase 2 APEX Trial Evaluating
8:03am
8-K
EX-99.1
w02b7863p w3yr
14 Nov 22
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2022 Financial Results
7:14am
8-K
EX-99.1
r45rygzm7myfhip
9 Aug 22
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2022 Financial Results
7:15am
424B5
7iw79w
15 Jun 22
Prospectus supplement for primary offering
5:16pm